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Abstract
Aims: To understand the relationship between insulin resistance (IR), assessed as 
estimated glucose disposal rate (eGDR), and microvascular/macrovascular complica-
tions in people with type 1 diabetes.
Materials and methods: Individuals with a confirmed diagnosis of type 1 dia-
betes were included in this cross- sectional study. BMI was categorised into nor-
mal weight (18.0– 24.9 kg m−2), overweight (25.0– 29.9 kg m−2) and obese groups 
(≥30.0 kg m−2). We categorised eGDR into four groups: eGDR >8, 6– 7.9, 4– 5.9 and 
<4 mg kg−1 min−1. Multiple logistic regression was used to identify associations with 
vascular complications, after adjusting for relevant confounders.
Results: A total of 2151 individuals with type 1 diabetes were studied. Median [in-
terquartile range (IQR)] age was 41.0 [29.0, 55.0] with diabetes duration of 20.0 
[11, 31] years. Odds ratio (OR) for retinopathy and nephropathy in obese compared 
with normal weight individuals was 1.64 (95% CI: 1.24– 2.19; p = 0.001) and 1.62 
(95% CI: 1.10– 2.39; p = 0.015), while the association with cardiovascular disease 
just failed to reach statistical significance (OR 1.66 [95% CI: 0.97– 2.86; p = 0.066]). 
Comparing individuals with eGDR ≥8  mg  kg−1  min−1 and <4  mg  kg−1  min−1 
showed OR for retinopathy, nephropathy and macrovascular disease of 4.84 (95% 
CI: 3.36– 6.97; p < 0.001), 8.35 (95% CI: 4.86– 14.34; p < 0.001) and 13.22 (95% CI: 
3.10– 56.38; p < 0.001), respectively. Individuals with the highest eGDR category 
(≥8 mg kg−1 min−1) had the lowest complication rates irrespective of HbA1c levels.
Conclusions: Obesity is prevalent in type 1 diabetes and diabetes complications are 
not only related to glucose control. IR, assessed as eGDR, is strongly associated with 
both microvascular and macrovascular complications, regardless of HbA1c levels.
K E Y W O R D S
insulin resistance, obesity, type 1 diabetes, complications
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1 |  INTRODUCTION
According to the National Institute for Clinical Excellence, 
type 1 diabetes affects over 370,000 adults in the United 
Kingdom1 and more than 1.6 million people are living with 
the condition in the United States.2 Based largely upon the 
findings of the Diabetes Control and Complications Trial,3 
various guidelines recommend intensive insulin regimes to 
achieve a HbA1c <6.5% or <7.0% (<48 or <53 mmol/mol), 
unless this target cannot be achieved due to disabling hypo-
glycaemia.4 Obesity and insulin resistance (IR) are increas-
ing in type 1 diabetes, partly related to lifestyle choices but 
also secondary to the condition itself. Subcutaneous insulin 
administration can induce peripheral IR both directly 5- 7 and 
indirectly through weight gain8 and treatment of repeated hy-
poglycaemia.9 Consequently, this can lead to the challenging 
clinical scenario of escalating insulin doses, further weight 
gain and increasing IR creating a vicious cycle. The weight 
gain can have detrimental vascular effects through the devel-
opment of an inflammatory and thrombotic milieu, typically 
associated with insulin- resistant states.10- 12
It has been proposed that people with type 1 diabetes 
and IR constitute a clinical entity, termed ‘double diabetes 
(DD).’13 However, the exact definition of this group has 
been problematic with early studies labelling those with au-
toimmune diabetes and a family history of type 2 as having 
DD.14,15 The definition of DD was subsequently refined to 
include type 1 diabetes individuals with features of the meta-
bolic syndrome, a subpopulation that showed adverse clinical 
outcome compared with the rest of type 1 diabetes group.16
Estimated glucose disposal rate (eGDR) is a marker of 
IR, derived from data using euglycaemic– hyperinsulinemic 
clamps in 24 individuals with type 1 diabetes.17 This is cal-
culated according to a formula that uses standard clinical 
measures including waist– hip ratio (alternatively, waist cir-
cumference or BMI), HbA1c and presence of hypertension. 
The strong correlation between eGDR and IR, using the 
gold standard clamp techniques, indicates this is a valuable 
marker to identify the presence of DD in those with type 1 
diabetes.17- 19 Previous work has demonstrated a relationship 
between IR and vascular complications in people with type 
1 diabetes while more recent prospective work linked eGDR 
with cardiovascular and all- cause mortality in this cohort.18- 26 
However, the exact contribution of eGDR and its components 
to risk of complications is not entirely clear, particularly in 
patients on modern management strategies.
We hypothesise that the risk of both microvascular dis-
ease and macrovascular complications in people with type 1 
diabetes is not only determined by glycaemic control and IR 
has a key role. Therefore, the main aims of this study were to 
explore (i) relationship between obesity, assessed as BMI and 
diabetes- related microvascular and macrovascular complica-
tions, (ii) relationship between IR, measured as eGDR, and 
diabetes complications and (iii) understand the association 
between vascular risk factors, obesity and IR.
2 |  METHODS
For this study, a cross- sectional design was used with elec-
tronic patient data from November 2016 to February 2018, 
reviewed in Leeds Teaching Hospital Trust in England, UK. 
Data were collected on a single timepoint using the following 
inclusion criteria: (i) confirmed diagnosis of type 1 diabetes 
for over 1 year and current treatment with insulin. Diagnosis 
of type 1 diabetes was defined as being recorded in the medi-
cal records by a consultant physician or senior trainee in dia-
betes: (ii) availability of recent weight and height data, (iii) 
age over 18 years old and (iv) BMI ≥ 18.0 kg/m2. Exclusion 
criteria were as follows: (i) diabetes aetiology is not con-
firmed or in doubt and (ii) having an established diagnosis of 
an eating disorder or a disorder related to body dysmorphia 
accompanied with a low BMI (<18.0 kg/m2). The study was 
classified as an audit and no ethical approval was deemed 
necessary as per local protocols. All data were anonymised 
before analysis.
2.1 | Outcome definitions
All outcomes were recorded from the most recent clinical in-
formation within the past 2 years preceding clinic attendance. 
BMI was categorised as healthy weight (18– 24.9  kg/m2), 
overweight (25– 30 kg/m2) and obese (>30 kg/m2). eGDR was 
used as a measure of IR and calculated using the formula; eG-
DRBMI = 19.02 − (0.22 × BMI, kg m−2) − (3.26 × hyper-
tension, presence) − (0.61 × HbA1c, %), whereby the presence 
of hypertension was defined by the actual blood pressures 
≥140/90  mmHg or current use of any anti- hypertensive 
agents.17,19 eGDR was categorised into four categories 
Novelty statement
In UK individuals with type 1 diabetes:
a. More than half of this population are overweight 
or obese, assessed using BMI.
b. While higher BMI showed an association with di-
abetes complications, estimated glucose disposal 
rate appeared to show an even stronger associa-
tion with both microvascular and macrovascular 
disease.
c. Estimated glucose disposal rate may be a useful 
adjunct marker for risk stratification in routine 
clinical practice.
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(<4, 4– 5.9, 6– 7.9 and >8 mg kg−1 min−1) based on previous 
work demonstrating a difference in mortality between these 
categories in a longitudinal observational study.19
Duration of diabetes was calculated using age at time 
of records review (years)  −  age at diagnosis (years). 
Retinopathy was defined as present if the observed abnor-
malities were more than simple background grade R1 alter-
ations (R1 = mild non- proliferative changes and absence of 
macular disease) in at least one eye using retinal photogra-
phy. Nephropathy was defined as estimated glomerular fil-
tration rate < 60 ml min−1 m−2 and/or history of persistent 
albuminuria. Persistent albuminuria was defined as Urine 
Albumin:Creatinine Ratio > 3.0 mg mmol−1 on more than 
one occasion. Cardiovascular disease was defined as a his-
tory of myocardial infarction, angina, coronary revascularisa-
tion, documented ischaemic heart disease, stroke or transient 
ischaemic attacks.
2.2 | Statistical analysis
Descriptive data were presented in mean  ±  SD, median 
[IQR] or number (%). One- way ANOVA or Kruskal– Wallis 
and Chi- square tests were used to compare baseline charac-
teristics among BMI categories for continuous and categori-
cal variables, respectively. Generalised linear regression was 
used to estimate the mean difference of blood pressure or 
lipid parameters among BMI category with adjustment for 
age, sex, diabetes duration, the use of antihypertensive or 
statin (where relevant), and HbA1c. To estimate mean differ-
ences of lipid parameters among eGDR category, the mean 
differences were adjusted for the same confounders as for 
BMI except for HbA1c, which is part of eGDR calculation. 
Multiple logistic regression was used to evaluate the asso-
ciation between presence of microvascular or macrovascular 
complications and BMI or eGDR categories. BMI and eGDR 
categories were presented as crude and adjusted odd ratio 
(OR) with age, gender, diabetes duration and HbA1c adjusted 
for BMI category; and age, gender and diabetes duration ad-
justed for eGDR category. Further adjustment for treatment 
effect including statins, anti- hypertensives and adjunct oral 
hypoglycaemic agents was carried out for both BMI and 
eGDR categories. We added clinically relevant variables to 
the models while avoiding ‘overfitting’. We also avoided in-
cluding any variable with missing data >10% into adjusted 
models. The percentage of missing data of each variable is 
presented in Table 1. SPSS version 25.0 (IBM Incorporation) 
was used for all analyses.
Given that HbA1c, BMI and presence of hypertension 
are part of eGDR calculation, adjustments for these vari-
ables were not made when analysing the association between 
eGDR and complications. A similar methodology has been 
used in the past for the analysis of eGDR.27
3 |  RESULTS
A total of 2375 individuals were identified for the study of 
whom 2151 met inclusion criteria. Reasons for exclusion 
are shown in Figure 1. Of 2151 individuals, median age was 
41.0 [29.0, 55.0] years, 53.8% were men, mean BMI was 
27.0 ± 4.9 kg m−2, median duration of diabetes was 20.0 (11, 
31)  years and mean HbA1c was 69.1  ±  17.5  mmol  mol
−1. 
Of 2094 individuals having HbA1c data, mean eGDR was 
6.31  ±  2.32  mg  kg−1  min−1. A summary of data from the 
initial screening process of eligible participants is shown in 
Table 1.
3.1 | Obesity, IR and diabetes- related 
complications
3.1.1 | Retinopathy
Retinopathy, defined as any change higher than retinopa-
thy grade R1, was present in 21.3% of the study cohort. For 
BMI, a significant increase in OR was seen with higher BMI 
category in an unadjusted model. After adjustment for age, 
gender, HbA1c and duration of diabetes, a similar pattern was 
observed, although less pronounced (Figure  2). When fur-
ther adjustments were made for statins, anti- hypertensives 
and adjuvant anti- glycaemic therapies, obese individuals still 
showed an increased frequency of retinal complications (ad-
justed OR 1.38 [95% CI: 1.02– 1.87; p = 0.04]) (Table S1).
When eGDR was used instead of BMI, large differences 
were seen in the unadjusted model and also in the model ad-
justed for age, gender and diabetes duration (Figure 3). These 
differences also remained significant after further adjustment 
for therapies other than insulin (adjusted OR 2.12, 2.02 and 
4.07 for eGDR 6– 7.9, 4– 5.9 and <4 mg kg−1 min−1, respec-
tively; p < 0.001 for all) (Table S1).
3.1.2 | Nephropathy
Nephropathy was present in 18.6% of patients. Comparing 
across BMI categories, crude OR showed no difference in 
rates of nephropathy between normal weight and over-
weight groups but there was a significant increase in obese 
individuals (crude OR 1.93 [95% CI: 1.35– 2.76; p < 0.001)]. 
However, after adjusting for age, gender, HbA1c and diabe-
tes duration, the degree to which obesity increased the odds 
was diminished (adjusted OR 1.62 (95% CI: 1.10– 2.39; 
p = 0.015]) (Figure 2) and indeed after further adjustment to 
include non- insulin therapies, no significant differences were 
seen across BMI cohorts (Table S1).
When analysing the relationship between eGDR and ne-
phropathy, a strong relationship was observed between falling 
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T A B L E  1  Baseline characteristics by BMI category (n = 2151).
Patient characteristic










Median age, years 37.0 [26.0, 53.0] 43.0 [30.0, 55.0] 47.0 [35.0, 59.0] <0.001 0
Gender, men 425 (51.1%) 485 (59.2%) 248 (49.6%) <0.001 0
Median duration of 
diabetes, years
17.0 [9, 29] 20.0 [11.0, 31.0] 24.0 [15.0, 34.0] <0.001 0
BMI, kg m−2 22.5 (1.7) 27.2 (1.4) 33.9 (3.7) <0.001 0
eGDR, mg kg−1 min−1 7.66 (1.83) 6.27 (1.89) 4.15 (2.03) <0.001 2.6 3.1, 2.6, 2.0
SBP, mmHg 128.8 (16.9) 133.7 (16.7) 138.4 (17.7) <0.001 0.5 0.7, 0.5, 0.2
DBP, mmHg 75.9 (9.4) 77.4 (8.7) 78.9 (9.7) <0.001 0.6 0.8, 0.6, 0.2
Presence of HTN, no 303 (36.7%) 421 (51.7%) 335 (67.3%) <0.001 0.6 0.7, 0.6, 0.4
Number of anti- 
hypertensives, no.
<0.001 0.4 0.1, 0.5, 0.8
None 635 (76.4%) 535 (65.6%) 241 (48.6%)
1 agent 127 (15.3%) 172 (21.1%) 123 (24.8%)
2 agents 47 (5.7%) 77 (9.4%) 94 (19.0%)
>3 agents 22 (2.6%) 31 (3.8%) 38 (7.8%)
.eGFR, ml min−1 m−2 <0.001 10.1 9.4, 11.0, 8.4
>90 649 (86.5%) 578 (79.7%) 350 (76.4%)
60– 89.9 70 (10.5%) 116 (16.0%) 75 (16.4%)
30– 59.9 11 (1.5%) 24 (3.3%) 29 (6.3%)
15– 29.9 6 (0.8%) 4 (0.6%) 2 (0.4%)
<15 5 (0.7%) 3 (0.4%) 2 (0.4%)
Mode of insulin delivery 0.838 0
MDI 64 (77.0%) 639 (78.0%) 398 (79.6%)
CSII 126 (15.1%) 120 (14.7%) 65 (13.0%)
Mixed insulin 65 (7.8%) 60 (7.3%) 37 (7.40%)
Total daily insulini, 
U kg−1 day−1
0.44 (0.31) 0.44 (0.27) 0.50 (0.40) 0.002 10.9 115, 9.5, 12.2
Use of adjuvant glycaemic 
therapy, no.
8 (1.0%) 34 (4.2%) 83 (16.6%) <0.001 0
Use of statin therapy, no 251 (30.2%) 346 (42.2%) 289 (57.8%) <0.001 0
HbA1c, mmol mol
−1 69.9 (19.0) 67.5 (16.4) 70.1 (16.2) 0.006 2.0 2.4, 2.0, 1.6
HbA1c, % 8.5 (1.7) 8.3 (1.5) 8.6 (1.5) 0.006 2.0 2.4, 2.0, 1.6
Total cholesterol, 
mmol L−1
4.51 (0.86) 4.57 (1.03) 4.57 (0.98) 0.487 18.9 18.9, 19.5, 
18.0
LDL- c, mmol L−1 2.25 (0.71) 2.40 (0.78) 2.41 (0.83) 0.004 46.9 48.0, 45.3, 
47.6
HDL- c, mmol L−1 1.78 (0.54) 1.61 (0.54) 1.63 (1.16) <0.001 37.9 39.5, 36.1, 
38.0
Triglycerides, mmol L−1 1.13 (0.82) 1.27 (0.79) 1.57 (0.97) <0.001 33.1 33.2, 32.4, 
34.4
Creatinine, mmol L−1 73.6 (47.0) 78.1 (61.3) 80.6 (62.4) 0.085 9.7 9.3, 11.0, 8.4
Urine ACRi 6.1 (36.2) 4.9 (39.9) 6.4 (22.1) 0.808 39.0 36.8, 39.6, 
41.8
(Continues)
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eGDR and the presence of nephropathy. After adjusting for 
age, gender and duration of diabetes, this strong relationship 
persisted (adjusted OR 1.98, 3.82 and 8.35 for eGDR 6– 7.9, 
4– 5.9 and <4 mg kg−1 min−1, respectively; p < 0.05 for all) 
(Figure  3) as it did when adjusting for therapeutic agents 
other than insulin (adjusted OR 1.71, 2.64 and 5.56 for eGDR 
6– 7.9, 4– 5.9 and <4  mg  kg−1  min−1; p  =  0.07, 0.001 and 
<0.001, respectively) (Table S1).
3.1.3 | Macrovascular complications
In an unadjusted model, differences in rates of cardiovascu-
lar events were seen in those whom were obese (crude OR 
1.88 [95% CI: 1.14– 3.11; p = 0.01]) but not in those whom 
were overweight (p = 0.75). However, the association found 
in obese individuals showed only a trend after adjusting for 
age, gender, HbA1c and diabetes duration (adjusted OR 1.66 
[95% CI: 0.97– 2.86; p = 0.07]) (Figure 2).
Lower eGDR, on the other hand, was markedly associ-
ated with the presence of macrovascular disease in the unad-
justed model. After adjustment for age, gender and duration 
of diabetes, adjusted OR for eGDR <4 mg kg−1 min−1 re-
mained highly significant (adjusted OR 13.22 [95% CI: 
3.10– 56.38; p < 0.001]) and a similar pattern was seen for 
those with eGDR 4– 5.9 mg kg−1 min−1 (adjusted OR 6.57 
[95% CI: 1.54– 28.00; p  =  0.01]) (Figure  3). Even after 
further adjustment for therapies other than insulin, the 
Patient characteristic










ALT, U L−1 20.7 (12.6) 22.6 (16.5) 26.1 (16.7) <0.001 23.5 23.3, 24.4, 
22.4
Retinopathy >grade 1, no 144 (17.3%) 176 (21.5%) 139 (27.8%) <0.001 0
Nephropathy, no. 80 (15.9%) 80 (16.6%) 77 (26.6%) <0.001 40.7 39.5, 41.0, 
42.0
Cardiovascular disease, no 31 (3.7%) 33 (4.0%) 34 (6.8%) 0.022 0
Abbreviations: ACR, albumin: creatinine ratio; ALT, alaninine aminotransferase; BMI, body mass index; CSII, continuous subcutaneous insulin injection; DBP, 
diastolic blood pressure; eGDR, estimated glucose disposal rate; eGFR, estimated glomerular filtration rate; HDL- c, high- density liporotein cholesterol; HTN, 
hypertension; LDL- c, low- density lipoprotein cholesterol; MDI, multiple daily dose insulin; SBP, systolic blood pressure.
TABLE 1 (Continued)
F I G U R E  1  Patient enrolment and 
reasons for exclusion
2,397 patients with T1DM were identified
2,151 patients were included for primary analysis
(2,094 patients with HbA1c data available 








39, missing BMI data
19, not currently on insulin
26, T1DM duration <1 year
139, missing T1DM duration
23, BMI <18kg/m2
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association between cardiovascular events and those with 
eGDR <4 mg kg−1 min−1 remained significant (adjusted OR 
5.87 [95% CI: 1.21– 28.50; p = 0.03]) (Table S1).
3.2 | Obesity, IR and metabolic parameters
In overweight and obese individuals, systolic and diastolic 
blood pressures were significantly higher when compared 
to normal weight patients (Table  1). These differences re-
mained significant after adjusting for age, sex, duration 
of diabetes and HbA1c as well as use of antihypertensive 
agents (Figure S1). HbA1c in normal weight, overweight 
and obese individuals were 69.9  ±  19.0, 67.5  ±  16.4 and 
70.1 ± 16.2 mmol mol−1, respectively (post- hoc Bonferroni, 
p  =  0.16 for normal weight vs. overweight and p  =  0.27 
for obese vs. overweight). Total daily insulin requirement 
in normal weight, overweight and obese individuals were 
0.44 ± 0.31, 0.44 ± 0.27 and 0.50 ± 0.40 U kg−1 day−1, re-
spectively (p = 0.002).
Obese individuals were found to have adverse lipid pro-
files compared to normal weight patients including an in-
crease in total cholesterol, triglycerides and LDL- cholesterol 
together with a decrease in HDL- cholesterol. The estimated 
mean difference of each lipid parameter remained significant 
after adjusting for age, gender, HbA1c, duration of diabetes 
and statins (p  =  0.03 for total cholesterol, and p  <  0.001 
for other lipid parameters). The effect of IR (assessed by 
eGDR category) on lipid parameters resembled that of obe-
sity, whereby individuals with lower eGDR had less desir-
able lipid profile including higher levels of total cholesterol, 
triglyceride and LDL- cholesterol as well as lower levels of 
HDL- cholesterol (Figure S2).
3.3 | Use of hypoglycaemic therapies other 
than insulin
Of the 125 individuals receiving adjuvant anti- hyperglycaemic 
therapy, 113 individuals were taking Metformin/Metformin 
modified release, 1 patient received a sodium glucose co- 
transporter- 2 (SGLT2) inhibitor, and 11 individuals were pre-
scribed glucagon- like peptide- 1 receptor agonist (GLP1- RA).
Patients receiving adjuvant hypoglycaemic therapies were 
older (47.5 ± 16.3 vs. 43.2 ± 16.6; p = 0.005), yet had a trend 
towards shorter duration of type 1 diabetes (20.1 ± 12.2 vs. 
22.2 ± 14.5; p = 0.072) with a female predominance (female 
64% vs. male 36%; p < 0.001). The odds ratio (OR) for receiv-
ing adjuvant anti- hyperglycaemic therapy was significantly 
higher in both overweight (OR 4.85, 95% CI: 2.22– 10.60, 
p < 0.001) and obese individuals (OR 21.09, 95% CI: 10.02– 
44.38, p < 0.001) compared to healthy weight patients after 
adjusting for age, gender, HbA1c and duration of diabetes.
3.4 | The relative contribution of 
HbA1c and eGDR components to diabetes- 
related complications
We further evaluated the association of diabetes- related 
complications and eGDR in the context of various lev-
els of HbA1c. Individuals with the highest eGDR category 
(≥8  mg  kg−1  min−1) had the lowest complication rates re-
gardless of HbA1c levels (Figure  4), indicating that HbA1c 
is not the sole predictor of microvascular and macrovascular 
complications in people with type 1 diabetes. The highest 
complication rate was demonstrated in those with low eGDR 
and high HbA1c. We also analysed the association between 
F I G U R E  2  Multiple logistic regression analysis showing odd ratio [95% CI] of retinopathy (>R1), nephropathy and cardiovascular disease 
by BMI category. †Adjusted for age, sex, diabetes duration and HbA1c. BMI, body mass index
Complicaon/prevalence Category n Crude OR [95%CI] p-value Adjusted OR† [95%CI] p-value
Renopathy
456/2,142 (21.3%)
Normal weight 811 ref. ref.
Overweight 799 1.302 [1.017, 1.667] 0.036 1.347 [1.035, 1.753] 0.027
Obese 488 1.802 [1.377, 2.357] <0.001 1.643 [1.235, 2.188] 0.001
Nephropathy 
233/1,269 (18.4%) 
Normal weight 499 ref. ref.
Overweight 479 1.066 [0.758, 1.500] 0.714 1.062 [0.733, 1.539] 0.750
Obese 285 1.928 [1.348, 2.756] <0.001 1.621 [1.100, 2.389] 0.015
Cardiovascular
98/2,142 (4.6%)
Normal weight 811 ref. ref.
Overweight 799 1.084 [0.657, 1.788] 0.752 0.990 [0.572, 1.713] 0.972
Obese 488 1.884 [1.143, 3.108] 0.013 1.664 [0.967, 2.863] 0.066
0 1 2 3 4 5
adjusted OR (95% CI)
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components of eGDR and complications with results demon-
strating that eGDR as a whole shows the strongest associa-
tion with complications (Table S2).
4 |  DISCUSSION
This study aimed to explore the clinical impact of obesity 
and IR on metabolic parameters and prevalence of vascular 
complications in people living with type 1 diabetes.
Glycaemic control, measured as HbA1c, is a key predic-
tor of future microvascular disease in individuals with type 1 
diabetes.3 However, we found that BMI may also determine 
predisposition to microvascular complications, particularly in 
relation to retinopathy, suggesting that weight also has a role. 
However, the association between BMI and microvascular 
disease was relatively modest. In contrast, eGDR showed a 
stronger association with microvascular disease even after 
correcting for age and diabetes duration. These findings in-
dicate that microvascular disease in type 1 diabetes is not 
only modulated by glycaemic control but also IR. Moreover, 
our data demonstrate that eGDR is more strongly linked to 
the development of microvascular complications than BMI. 
A largely similar pattern was observed for macrovascular 
disease; obese individuals had increased prevalence of car-
diovascular disease but the association between BMI and 
macrovascular complications lost significance after adjusting 
for relevant confounders. On the other hand, eGDR was as-
sociated with the presence of macrovascular disease with or 
without adjustment for confounders. It should be noted that 
previous work has shown a J- shaped or U- shaped association 
between BMI and mortality in type 1 diabetes individuals,28 
F I G U R E  3  Multiple logistic regression analysis showing odd ratio [95% CI] of retinopathy (>R1), nephropathy and cardiovascular disease by 
eGDR category. ‡With adjustment for age, sex and duration of type 1 diabetes mellitus
Complicaon/prevalence Category n Crude OR [95%CI] p-value Adjusted OR‡ [95%CI] p-value
Renopathy
449/2,087 (21.5%) 
eGDR >8 602 ref. ref.
eGDR 6 - 7.9 508 2.427 [1.721, 3.421] <0.001 2.215 [1.559, 3.147] <0.001
eGDR 4-5.9 616 2.885 [2.081, 3.998] <0.001 2.283 [1.604, 3.249] <0.001
eGDR <4 361 5.629 [3.996, 7.929] <0.001 4.842 [3.363, 6.970] <0.001
Nephropathy 
232/1,260 (18.4%)
eGDR >8 375 ref. ref.
eGDR 6 - 7.9 305 2.327 [1.331, 4.068] 0.003 1.979 [1.122, 3.492] 0.018
eGDR 4-5.9 362 5.414 [3.279, 8.939] <0.001 3.823 [2.238, 6.532] <0.001
eGDR <4 218 10.983 [6.547, 18.422] <0.001 8.345 [4.856, 14.340] <0.001
Cardiovascular
98/2,087 (4.7%)
eGDR >8 602 ref. ref.
eGDR 6 - 7.9 508 7.879 [1.770, 35.080] 0.007 4.232 [0.922, 19.427] 0.064
eGDR 4-5.9 616 24.211 [5.850, 100.196] <0.001 6.569 [1.541, 27.999] 0.011
eGDR <4 361 34.259 [8.205, 143.055] <0.001 13.218 [3.099, 56.382] <0.001
0 5 10 15
adjusted OR (95% CI)
F I G U R E  4  The prevalence rates of diabetes- related complications by HbA1c and eGDR categories (n = 2094). Left panel, retinopathy 
grade > R1; middle panel, nephropathy; right panel, cardiovascular disease. *Nephropathy, n = 1270
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which may have played a role in the stronger association of 
eGDR with complications in our study. However, this J- like 
effect of BMI would have been minimised in the current work 
by excluding individual with BMI<18 kg m−2 from the study.
The relationship between IR, measured as eGDR, and 
presence of both microvascular and macrovascular compli-
cations in this work is well- aligned with previous studies 
in this area.23- 26 Advantages of our study include the con-
temporary and relatively large cohort of patients analysed as 
well as the in- depth investigation of eGDR and its metabolic 
components. Overall, our data suggest that eGDR measure-
ment can be useful clinically to further help stratify risk of 
complications in people with type 1 diabetes. Indeed, a re-
cent nation- wide prospective study from Sweden, including 
17,050 individuals with type 1 diabetes, demonstrated an 
inverse correlation between eGDR and both cardiovascular 
and all- cause mortality over a 7.1- year follow- up period.19 
This study also showed that survival in individuals with 
eGDR ≥ 8 mg kg−1 min−1 was similar to people without di-
abetes. In keeping with this, we found that those with eGDR 
≥8 mg kg−1 min−1 had the lowest prevalence of macrovas-
cular complications. The same also applied to microvascular 
disease, suggesting that eGDR may also be a useful marker to 
predict the development of these complications.
Just like HbA1c, a key advantage of eGDR is the continu-
ous nature of this variable, making assessment of future vas-
cular risk relatively simple. Unlike HbA1c however, eGDR 
includes other key measures that are implicated in vascular 
pathology and influenced by IR. Therefore, eGDR is an IR 
marker that helps to better stratify the risk of diabetes com-
plications in those with type 1 diabetes than separately using 
each of its components. Taken together, a reduction in HbA1c 
may seem protective but this is not necessarily the case if 
the drop in HbA1c is associated with a significant decrease 
in eGDR (and hence an increase in IR). In support of this, 
our data show that high HbA1c per se was not associated with 
complications in the presence of high eGDR. In contrast, the 
combination of high HbA1c and low eGDR showed clear as-
sociations with complications, emphasising the importance 
of IR in predisposition to microvascular and macrovascular 
disease.
Future prospective studies are required to answer a num-
ber of clinically relevant questions, including (1) what is the 
optimal cut- off of eGDR that should be implemented in rou-
tine clinical practice? (2) what are the best management strat-
egies to modify eGDR and crucially, (3) is eGDR a measure 
that people with type 1 diabetes connect to and understand? 
While a multifactorial intervention in type 1 diabetes is rou-
tine practice, this is not always the case in the younger age 
group where the focus is on glycaemia. Incorporating eGDR 
into routine practice may help healthcare professionals and 
patients appreciate the importance of risk factors other than 
glucose levels, potentially improving long- term outcome in 
people with type 1 diabetes, particularly those whom are in-
sulin resistant. Also, this will potentially help to explore the 
effects of adjuvant therapies such as SGLT2 inhibitors and 
GLP1- RA on the development of complications by monitor-
ing changes in eGDR.29 A large proportion of patients were 
overweight/obese in our study but there was relatively little 
use of adjunctive glycaemic therapies (other than metformin), 
despite data showing weight loss and/or glycaemic improve-
ment with GLP- 1RA and sGLT2 inhibitors.29
This study has several strengths. First, it was conducted 
with real- world data and using a contemporary cohort of 
patients, reflecting routine clinical practice and making re-
sults more generalisable. Second, it is a single- centre study 
with uniform data collection and relatively large sample size. 
Third, there was a good spread of ages with high rate of mi-
crovascular complications, consistent with the real- world 
nature of the data. Finally, our results show that eGDR is a 
strong marker of both microvascular and macrovascular com-
plications, suggesting it can be used to predict risk and mon-
itor response to a specific management strategy.
There are several limitations to this work. First, data 
were collected using a cross- sectional study design, which 
can only establish associations and is unable to demonstrate 
a causal relationship. Second, data analysis employed dif-
ferent adjustments for BMI and eGDR but this is due to the 
inability to adjust for components of eGDR. Also, caution 
should be exercised with data interpretation given testing for 
associations on multiple covariates and the use of a number 
of models. Third, information on current/previous smoking 
was lacking and as such we were unable to ascertain if there 
was any pattern in smoking habits observed and thus were 
unable to adjust for this important confounder. Fourth, the 
limited ethnic diversity of the group studied makes general-
isability of the results questionable and larger studies involv-
ing multiple centres and different countries are warranted to 
fully understand the potential role of eGDR in routine clinical 
practice. Fifth, the validity of eGDR in conditions associated 
with changes in HbA1c, such as haemoglobinopathies and ad-
vanced renal failure, remains unknown. Finally, it is import-
ant to note that not all studies have found strong correlation 
between IR determined by clamp techniques and eGDR.30 
However, eGDR correlates well with diabetes complications 
and as such it has the potential to serve as a vascular risk 
marker, and future longitudinal studies are required to inves-
tigate this possibility.
In conclusion, this study, in a contemporary group of 
people with type 1 diabetes, shows that eGDR is strongly 
associated with the presence of both microvascular and mac-
rovascular complications, regardless of HbA1c. This indicates 
that eGDR may be a useful adjunct marker for risk stratifica-
tion in routine practice. Future prospective studies are war-
ranted to evaluate the role of modulating eGDR in preventing 
vascular complications in people with type 1 diabetes, which 
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will help to fully establish the role of this variable in daily 
clinical management of type 1 diabetes.
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